Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

La Jolla Institute Discovers Novel Tumor Suppressor
La Jolla Institute for Allergy and Immunology researchers studying an enzyme believed to play a role in allergy onset, instead have discovered its previously unknown role as a tumor suppressor that may be important in myeloproliferative diseases and some types of lymphoma and leukemia. Myeloproliferative diseases are a group of disorders characterized by an overproduction of blood cells by the bone marrow and include chronic myeloid leukemia. Lymphoma and leukemia are cancers of the blood.
generic viagra online
Is There Long-Term Brain Damage After Bypass Surgery? More Evidence Puts The Blame On Heart Disease
Brain scientists and cardiac surgeons at Johns Hopkins have evidence from 227 heart bypass surgery patients that long-term memory losses and cognitive problems they experience are due to the underlying coronary artery disease itself and not ill after-effects from having used a heart-lung machine.
News of the day
BioCis Pharma Starts A Phase I Clinical Trial With A New Cancer Drug
BioCis Pharma Ltd., a privately-held drug development company with its headquarters in Turku, Finland, has started Phase I clinical testing of ProtoCure(TM) intravesical instillation solution, a novel anti-cancer drug for urinary bladder cancer. ProtoCure is based on a new mechanism of action discovered and developed by BioCis Pharma which effectively prevents cancer growth and proliferation locally.
Health Insurance

Changing Paradigms In Hereditary Angioedema: A Focus On Timely Diagnosis And New Therapies

Hereditary angioedema (HAE) is an autosomal dominant disease affecting approximately 10,000 people in the United States. HAE causes recurrent attacks of intense localized edema involving the skin, airway, and visceral organs. While chronic therapy with attenuated androgens or plasmin inhibitors has been the mainstay of HAE therapy, many new therapies for prophylaxis and acute treatment are on the horizon. It is important for physicians to understand the signs and symptoms of patients who present with HAE and to be familiar with the conventional and emerging therapies available to treat them. To address the need for current education on HAE, Robert Michael Educational Institute LLC (RMEI) and Postgraduate Institute for Medicine (PIM) are jointly sponsoring a complimentary continuing medical education self-study audio activity titled Changing Paradigms in Hereditary Angioedema: A Focus on Timely Diagnosis and New Therapies. This activity is supported by an educational grant from ViroPharma Incorporated. Faculty for this continuing medical education activity include the following experts in allergy and immunology: Allen P. Kaplan, MD, from Medical University of South Carolina in Charleston, South Carolina; Bruce L. Zuraw, MD, from the University of California School of Medicine in San Diego, California; and Paula J. Busse, MD, from the Mount Sinai School of Medicine in New York. "Quality continuing medical education is vital to developing and increasing knowledge and skills and enhancing patient care," says Robert Michael Educational Institute LLC President and CEO, Robert M. Colleluori. RMEI is a medical education company that specializes in independent, certified and non-certified education. The goal of all certified RMEI educational offerings is to promote a spirit of lifelong learning and continuous professional development. RMEI works closely with medical experts to design activities that improve diagnosis and treatment leading to better outcomes for patients. These activities include national and international symposia, teleconferences, live meetings, enduring print materials, and interactive Internet programs. Robert Michael Educational Institute LLC


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009